Dr. Reddy's Laboratories Ltd. | DRREDDY | NSE - Pharmaceuticals
INR in Million. Fiscal year ends in March. Figures are consolidated and restated..
Upgrade Membership to see 10 year accurate financial statements.
Chart | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Cash and cash equiva... |
![]() | 3,865 | 2,638 | 2,228 | 2,053 | 14,829 |
Short-term investment |
![]() | 14,271 | 18,330 | 22,529 | 23,687 | 19,895 |
Accounts receivables |
![]() | 37,986 | 40,527 | 39,869 | 50,278 | 49,641 |
Inventories |
![]() | 28,528 | 29,089 | 33,579 | 35,067 | 45,412 |
Deferred income taxes |
![]() | 0 | 0 | 0 | 0 | 0 |
Other current assets |
![]() | 12,187 | 14,400 | 12,896 | 14,906 | 15,726 |
Total current assets |
![]() | 96,837 | 104,984 | 111,101 | 125,991 | 145,503 |
Gross property plant... |
![]() | 50,281 | 49,733 | 49,127 | 47,779 | 47,322 |
Accumulated Depriciat... |
![]() | 0 | 0 | 0 | 0 | 0 |
Net property, plant and Eq... |
![]() | 50,281 | 49,733 | 49,127 | 47,779 | 47,322 |
Work in Progress |
![]() | 6,095 | 7,678 | 4,725 | 4,364 | 9,539 |
Miscellaneous Investment |
![]() | 6,826 | 5,409 | 4,073 | 3,884 | 9,101 |
Deferred income taxes |
![]() | 6,784 | 9,972 | 7,717 | 16,578 | 13,431 |
Intangible assets |
![]() | 41,413 | 41,643 | 42,734 | 26,798 | 35,248 |
Goodwill |
![]() | 4,763 | 5,331 | 4,659 | 4,913 | 5,599 |
Other long-term assets |
![]() | 5,166 | 693 | 520 | 1,946 | 425 |
Total non-current assets |
![]() | 121,328 | 120,459 | 113,555 | 106,262 | 120,665 |
Total assets |
![]() | 218,165 | 225,443 | 224,656 | 232,253 | 266,168 |
Short-term debt |
![]() | 43,626 | 25,562 | 12,125 | 16,532 | 23,145 |
Accounts Payable... |
![]() | 10,569 | 13,345 | 13,671 | 15,248 | 18,109 |
Provisions |
![]() | 6,607 | 5,917 | 4,970 | 5,241 | 6,403 |
Taxes Payable |
![]() | 0 | 0 | 0 | 0 | 0 |
Deferred Revenues |
![]() | 0 | 0 | 0 | 0 | 0 |
Capital Leases |
![]() | 0 | 0 | 0 | 0 | 0 |
Other current liabilities |
![]() | 23,397 | 24,114 | 28,207 | 35,120 | 33,381 |
Total current liabilities |
![]() | 84,199 | 68,938 | 58,973 | 72,141 | 81,038 |
Long-term debt |
![]() | 5,449 | 25,089 | 22,000 | 1,304 | 6,299 |
Investments Liabilities |
![]() | 0 | 0 | 0 | 0 | 0 |
Deferred tax liabilities |
![]() | 1,620 | 1,950 | 473 | 20 | 289 |
Provisions |
![]() | 842 | 817 | 793 | 745 | 508 |
Capital Leases |
![]() | 0 | 0 | 0 | 0 | 0 |
Other longterm liabilities |
![]() | 3,434 | 2,933 | 2,181 | 2,055 | 1,617 |
Total non-current liabilities |
![]() | 11,345 | 30,789 | 25,447 | 4,124 | 8,713 |
Total liabilities |
![]() | 95,544 | 99,727 | 84,420 | 76,265 | 89,751 |
Share Capital |
![]() | 829 | 830 | 830 | 831 | 832 |
Share premium |
![]() | 0 | 0 | 0 | 0 | 0 |
Retained earnings |
![]() | 121,792 | 124,886 | 139,406 | 155,157 | 175,585 |
Accumulated other equity |
![]() | 0 | 0 | 0 | 0 | 0 |
Preferred Stock |
![]() | 0 | 0 | 0 | 0 | 0 |
Minority Interest |
![]() | 0 | 0 | 0 | 0 | 0 |
Total Equity |
![]() | 122,621 | 125,716 | 140,236 | 155,988 | 176,417 |
Total Liabilities and Equity |
![]() | 218,165 | 225,443 | 224,656 | 232,253 | 266,168 |
Cash per Share |
![]() | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
Cash, Current Inv Per share |
![]() | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |